Cargando…
The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer
BACKGROUND: There is a long-time unmet need for a means to detect breast cancer (BC) using blood. Although mammography is accepted as the gold standard for screening, a blood-based diagnostic can complement mammography and assist in the accurate detection of BC in the diagnostic process period of ea...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722095/ https://www.ncbi.nlm.nih.gov/pubmed/34979986 http://dx.doi.org/10.1186/s12885-021-09055-1 |
_version_ | 1784625460151320576 |
---|---|
author | Lee, Youn Ju Kim, Young Choi, Bo Bae Kim, Je Ryong Ko, Hye Mi Suh, Kyoung Hoon Lee, Jin Sun |
author_facet | Lee, Youn Ju Kim, Young Choi, Bo Bae Kim, Je Ryong Ko, Hye Mi Suh, Kyoung Hoon Lee, Jin Sun |
author_sort | Lee, Youn Ju |
collection | PubMed |
description | BACKGROUND: There is a long-time unmet need for a means to detect breast cancer (BC) using blood. Although mammography is accepted as the gold standard for screening, a blood-based diagnostic can complement mammography and assist in the accurate detection of BC in the diagnostic process period of early diagnosis. We have previously reported the possible use of thioredoxin 1 (Trx1) in serum as a novel means to detect BC. In the present study, we validated the clinical utility of Trx1 to identify BC by testing sera from biopsy-confirmed cancer patients and women without cancer. METHODS: We have generated monoclonal antibodies against Trx1 and developed an ELISA kit that can quantitate Trx1 in sera. The level of Trx1 was determined in each serum from women without cancer (n = 114), as well as in serum from patients with BC (n = 106) and other types of cancers (n = 74), including cervical, lung, stomach, colorectal, and thyroid cancer. The sera from BC patients were collected and classified by the subjects’ age and cancer stage. In addition to the Trx1 levels of BC patients, several pathological and molecular aspects of BC were analyzed. Test results were retrospectively compared to those from mammography. Each test was duplicated, and test results were analyzed by ROC analysis, one-way ANOVA tests, and unpaired t-tests. RESULTS: The mean level of Trx1 from women without cancer was 5.45 ± 4.16 (±SD) ng/ml, that of the other malignant cancer patient group was 2.70 ± 2.01 ng/ml, and that from the BC group was 21.96 ± 6.79 ng/ml. The difference among these values was large enough to distinguish BC sera from non-BC control sera with a sensitivity of 97.17% and specificity of 94.15% (AUC 0.990, p < 0.0001). Most Trx1 levels from BC patients’ sera were higher than the cut-off value of 11.4 ng/ml regardless of age, stage, histological grade, type, and specific receptors’ expression profile of BC. The level of Trx1 could rescue women from most cases of misread or incomplete mammography diagnoses. CONCLUSION: These results indicated that the blood level of Trx1 could be an effective and accurate means to assist the detection of BC during the early diagnosis period. |
format | Online Article Text |
id | pubmed-8722095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87220952022-01-06 The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer Lee, Youn Ju Kim, Young Choi, Bo Bae Kim, Je Ryong Ko, Hye Mi Suh, Kyoung Hoon Lee, Jin Sun BMC Cancer Research Article BACKGROUND: There is a long-time unmet need for a means to detect breast cancer (BC) using blood. Although mammography is accepted as the gold standard for screening, a blood-based diagnostic can complement mammography and assist in the accurate detection of BC in the diagnostic process period of early diagnosis. We have previously reported the possible use of thioredoxin 1 (Trx1) in serum as a novel means to detect BC. In the present study, we validated the clinical utility of Trx1 to identify BC by testing sera from biopsy-confirmed cancer patients and women without cancer. METHODS: We have generated monoclonal antibodies against Trx1 and developed an ELISA kit that can quantitate Trx1 in sera. The level of Trx1 was determined in each serum from women without cancer (n = 114), as well as in serum from patients with BC (n = 106) and other types of cancers (n = 74), including cervical, lung, stomach, colorectal, and thyroid cancer. The sera from BC patients were collected and classified by the subjects’ age and cancer stage. In addition to the Trx1 levels of BC patients, several pathological and molecular aspects of BC were analyzed. Test results were retrospectively compared to those from mammography. Each test was duplicated, and test results were analyzed by ROC analysis, one-way ANOVA tests, and unpaired t-tests. RESULTS: The mean level of Trx1 from women without cancer was 5.45 ± 4.16 (±SD) ng/ml, that of the other malignant cancer patient group was 2.70 ± 2.01 ng/ml, and that from the BC group was 21.96 ± 6.79 ng/ml. The difference among these values was large enough to distinguish BC sera from non-BC control sera with a sensitivity of 97.17% and specificity of 94.15% (AUC 0.990, p < 0.0001). Most Trx1 levels from BC patients’ sera were higher than the cut-off value of 11.4 ng/ml regardless of age, stage, histological grade, type, and specific receptors’ expression profile of BC. The level of Trx1 could rescue women from most cases of misread or incomplete mammography diagnoses. CONCLUSION: These results indicated that the blood level of Trx1 could be an effective and accurate means to assist the detection of BC during the early diagnosis period. BioMed Central 2022-01-03 /pmc/articles/PMC8722095/ /pubmed/34979986 http://dx.doi.org/10.1186/s12885-021-09055-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Lee, Youn Ju Kim, Young Choi, Bo Bae Kim, Je Ryong Ko, Hye Mi Suh, Kyoung Hoon Lee, Jin Sun The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer |
title | The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer |
title_full | The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer |
title_fullStr | The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer |
title_full_unstemmed | The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer |
title_short | The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer |
title_sort | blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722095/ https://www.ncbi.nlm.nih.gov/pubmed/34979986 http://dx.doi.org/10.1186/s12885-021-09055-1 |
work_keys_str_mv | AT leeyounju thebloodlevelofthioredoxin1asasupportingbiomarkerinthedetectionofbreastcancer AT kimyoung thebloodlevelofthioredoxin1asasupportingbiomarkerinthedetectionofbreastcancer AT choibobae thebloodlevelofthioredoxin1asasupportingbiomarkerinthedetectionofbreastcancer AT kimjeryong thebloodlevelofthioredoxin1asasupportingbiomarkerinthedetectionofbreastcancer AT kohyemi thebloodlevelofthioredoxin1asasupportingbiomarkerinthedetectionofbreastcancer AT suhkyounghoon thebloodlevelofthioredoxin1asasupportingbiomarkerinthedetectionofbreastcancer AT leejinsun thebloodlevelofthioredoxin1asasupportingbiomarkerinthedetectionofbreastcancer AT leeyounju bloodlevelofthioredoxin1asasupportingbiomarkerinthedetectionofbreastcancer AT kimyoung bloodlevelofthioredoxin1asasupportingbiomarkerinthedetectionofbreastcancer AT choibobae bloodlevelofthioredoxin1asasupportingbiomarkerinthedetectionofbreastcancer AT kimjeryong bloodlevelofthioredoxin1asasupportingbiomarkerinthedetectionofbreastcancer AT kohyemi bloodlevelofthioredoxin1asasupportingbiomarkerinthedetectionofbreastcancer AT suhkyounghoon bloodlevelofthioredoxin1asasupportingbiomarkerinthedetectionofbreastcancer AT leejinsun bloodlevelofthioredoxin1asasupportingbiomarkerinthedetectionofbreastcancer |